NKTR 16-214-02: A Phase 1/2, Open Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

December 01, 2017
Cancer - Lung, Solid Tumors
Principal Investigator: unassigned
Renal cell cancer, renal cell carcinoma, NSCLC PD-L1, urothelial cancer, advanced cancer